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1  | INTRODUC TION
Liver transplant recipients (LTR) have an increased risk of developing 
invasive candidiasis (IC), a life‐threatening infection associated with 
mortality rates up to 70%.1‐3 Prompt administration of adequate 
antifungal treatment has demonstrated to improve the outcome of 
patients with IC.4,5 The choice of the most appropriate antifungal 
agent in LTR depends on various factors, including patient's patho‐
physiology, disease severity, and Candida species.3 Recent guidelines 
recommend the use of fluconazole in stable patients who do not 
present risk factors for azole resistance.6,7 Although therapeutic 
drug monitoring (TDM) is not routinely recommended due to flu‐
conazole predictable PK profile and renal elimination,8 TDM‐guided 
dosing adaptation could optimize drug exposure in selected patient 
populations (ie, pediatric patients or those undergoing renal replace‐
ment therapies).9,10 Fluconazole exposure in LTR may be affected by 
complex pathophysiological conditions and by unstable renal func‐
tion. Additionally, dosing adaptation of fluconazole based only on 
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Abstract
Background: Fluconazole represents a common antifungal option for the treatment 
of Candida infections in liver transplant recipients. Although adequate antifun‐
gal exposure is known to correlate with favorable outcomes in patients with inva‐
sive candidiasis, therapeutic drug monitoring (TDM) of fluconazole is currently not 
recommended.
Methods: We conducted a retrospective study including adult liver transplant re‐
cipients receiving fluconazole for invasive candidiasis and undergoing TDM. We as‐
sessed the correlation between clinical variables, fluconazole trough plasma levels 
(Cmin), and outcome.
Results: Twenty‐seven patients (74% males; median age 57 years) were included. 
Abdominal candidiasis was the most frequent infection (56%). Median duration of 
fluconazole therapy was 17 days (IQR 9‐21). Fluconazole median Cmin was 11.0 mg/L 
(range 2.4‐30.6 mg/L). Five (19%) patients required TDM‐guided fluconazole dose 
increase. All‐cause in hospital mortality was 33%. Fluconazole Cmin >11 mg/L signifi‐
cantly correlated with clinical success (OR 8.78, 95% CI 1.13‐67.8, P = 0.04).
Conclusions: Our study identified decreased fluconazole Cmin as a factor associated 
with negative outcomes in liver transplant recipients with Candida infection. TDM of 
fluconazole may be advisable in this patient population.
K E Y W O R D S
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creatinine clearance (CrCl) estimated values might result in inappro‐
priate exposure due to the poor performance that CrCl formulas may 
have in predicting glomerular filtration rate in this population.11,12 
For this reason, since several years our institution performs TDM of 
fluconazole in LTR with the intent of individualizing drug exposure.
Aim of the study was to analyze the clinical characteristics and 
the factors associated with fluconazole trough levels (Cmin) in a co‐
hort of LTR treated for confirmed or suspected Candida infections.
2  | METHODS
2.1 | Study population
A retrospective, observational study was conducted at a 1100‐bed 
tertiary care university hospital performing liver transplants since 
2004. Adult (aged 18 and older) orthotopic LTR undergoing at least 
one determination of fluconazole Cmin during the period August 
2009‐August 2016 were included. Only the first episode treated 
with fluconazole was considered for each patient. Fluconazole 
was administered for proven or suspected fungal infection due to 
Candida spp. Proven infection was defined as recovery of Candida 
spp from a normally sterile site in presence of signs and symptoms of 
infection, as previously reported.13 Suspected candidiasis was based 
on clinicians’ judgment in presence of risk factors for Candida infec‐
tion along with clinical, radiological, or laboratory evidence consist‐
ent with an infectious disease process. Identification of isolates and 
antimicrobial susceptibility profiles were performed as previously 
described.14 Patients’ demographics, timing from liver transplant, 
site of infection, type of Candida strain, fluconazole dosage, flucona‐
zole Cmin, and outcome were collected through electronic databases. 
Changes in liver enzymes and kidney function during fluconazole 
treatment were also recorded. Clinical success during fluconazole 
treatment was defined as cure or significant improvement of signs 
and symptoms of infection along with microbiological success, de‐
fined as eradication if follow‐up culture results were negative for 
Candida, or presumed eradication if follow‐up blood cultures were 
not available but the clinical outcome was defined as success. Failure 
of response was defined as no significant improvement in signs and 
symptoms, death, or positive follow‐up blood culture results. In‐hos‐
pital mortality was defined as death during hospitalization in which 
fluconazole treatment and TDM were performed.
The local institutional review board approved the study, and 
written patient consent was waived because of the retrospective 
nature of the study.
2.2 | Fluconazole treatment and TDM
According to the Summary of Product Characteristics, flucona‐
zole daily dose up to 400 mg/d is suggested for the treatment of 
IC in adult patients.15 In presence of impaired renal function (CrCl 
<50 mL/min) dose reduction of 50% is recommended.15 Fluconazole 
initial dosage was based on the treating physician's judgment and 
subsequently adjusted according to real‐time TDM.
Since many years fluconazole TDM is performed at our insti‐
tution by means of a validated HPLC technique and is available for 
all hospitalized patients receiving fluconazole upon request of the 
treating physician.16 Since 2009, fluconazole levels are routinely de‐
tected and electronically recorded among LTR receiving fluconazole 
through monitoring of Cmin and peak plasma levels. Based on the 
results of TDM, dose adjustments for LTR were recommended by 
an experienced clinical pharmacologist with the purpose of main‐
taining Cmin close to 10 mg/L. A dose increase was suggested for 
fluconazole concentrations below the desired level (Cmin <8 mg/L). 
Conversely, fluconazole dose was usually reduced when Cmin was 
more than twice the target level. Subsequent Cmin assessments fol‐
lowing dose adjustments were performed in order to confirm the 
achievement of target Cmin.
This approach is finalized to achieve the pharmacodynamics 
target of efficacy, defined as an area under the concentration‐time 
curve/MIC (AUC/MIC) ratio >100 against all fluconazole‐suscep‐
tible strains of Candida	 (MIC	≤2	mg/L,	with	MIC	 tested	 according	
to EUCAST methodology).17,18 Fluconazole Cmin were assessed at 
steady state after at least 3‐5 days of treatment.
2.3 | Statistical analysis
Continuous and categorical data were reported as mean ± SEM or 
median (25th and 75th percentile) and frequency distributions, re‐
spectively. Categorical variables were evaluated using chi‐square or, 
when appropriate, the two‐tailed Fisher's exact test. To determine 
correlations between two continuous variables, a Spearman corre‐
lation coefficient was calculated. Mann‐Whitney U test was used 
for comparing two groups. Logistic regression analysis was used to 
identify the variables correlated to clinical success among LTR with 
Candida infection. Variables with statistically significant association 
on univariate analysis were included in a multivariable binary logistic 
regression model. The area under the receiver‐operating character‐
istic (ROC) curve and Youden's Index were calculated to established 
cut‐off values for the variables with highest sensitivity and specific‐
ity for clinical success. Analyses were performed using SPSS v. 20.0 
(IBM, SPSS). All tests were two‐tailed, and a P value >0.05 was de‐
termined to represent statistical significance.
3  | RESULTS
A total of 27 liver transplant recipients (LTR) underwent at least one 
fluconazole TDM during the study period. Patients’ characteristics 
are summarized in Table 1. Twenty (74%) patients were males and 7 
(26%) females. Median age was 57 years (IQR 52.0‐60.3). Conditions 
leading to liver transplant included HCV‐related cirrhosis, (12/27, 
44%) alcoholic liver cirrhosis (8/27, 30%), HBV‐related cirrhosis 
(4/27, 15%), primary biliary cirrhosis (2/27, 7%), and fulminant hepa‐
titis B (1/27, 4%). Concomitant HCC was detected in 10 cases (37%). 
Median MELD score at transplantation was 17.5 (IQR 14.0‐23.3) 
with 50% of patients presenting with Child's B disease. Risk factors 
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associated with development of IC included the use of broad‐spec‐
trum antibiotics within 30 days prior of the start of fluconazole 
(24/27, 89%), recent (<6 months) abdominal or biliary tract surgery 
(14/27, 52%), severe renal impairment (4/27, 15%), and concomitant 
CMV reactivation (3/27, 11%). Candida infection was microbiologi‐
cally confirmed in 19 (70%) cases, and C albicans represented the 
most frequently isolated species (58%). All strains were reported as 
susceptible to fluconazole. Intra‐abdominal infections accounted for 
56% of infections (three peritonitis and 12 abdominal collection), 
followed by cholangitis (8/27, 30%), bloodstream infections (3/27, 
11%), and esophagitis (1/27, 4%). Concomitant bacterial infections 
were reported in 12 (44%) patients.
Median time from transplantation to the initiation of fluco‐
nazole treatment was 42 days (IQR 10‐406). Median duration of 
fluconazole therapy was 17 days (IQR 9‐21). All patients received 
intravenous fluconazole. Overall, median maintenance dose of flu‐
conazole (after an initial loading dose between 800 and 200 mg) 
ranged from 2.7 to 7.27 mg/kg/d. Fluconazole was dosed accord‐
ing to the Summary of Product Characteristics (SPC) in 24 patients 
(85%), while 4 (15%) patients with normal renal function received an 
initial dose below 6 mg/Kg/d according to the treating physician's 
judgment. All patients received concomitant immunosuppressive 
therapy.
Fluconazole Cmin ranged from 2.4 to 30.6 mg/L. Median fluco‐
nazole Cmin was 11.0 (7.9; 15.6) mg/L at first TDM and 11.6 mg/L 
(8.1; 16.6) after TDM‐guided dosage adjustments. Overall, 18 (67%) 
patients achieved fluconazole Cmin above 10 mg/L during treatment 
and 15 (56%) of these had Cmin >11 mg/L. Five out of 27 (19%) pa‐
tients did not achieve fluconazole Cmin >8 mg/L in the first determina‐
tion and required dose increase. After dose adjustments, fluconazole 
Cmin >8 mg/L was achieved in 25 (93%) patients. Two patients did not 
achieve concentrations >8 mg/L during treatment: one was an HIV‐
positive patient receiving fluconazole for esophageal candidiasis 
and one was a patient hospitalized in ICU with candidemia receiving 
fluconazole doses up to 500 mg/d. Median fluconazole dose (initial 
or after dose adjustment) resulting in Cmin concentration >8 mg/L 
was 4.2 mg/kg/d (IQR, 3.5‐5.8). The four patients receiving reduced 
Characteristic N = 27
Enterobacteriaceae 4/12 (33)
Other 2/12 (17)
Fluconazole treatment duration (d, IQR) 17 (9‐21)
Concomitant immunosuppressive therapy (%)
Tacrolimus 17 (63)
Cyclosporin A 8 (30)
Everolimus 2 (7)
Note: Results are expressed as percentage (%) or median and interquar‐
tile range (IQR).
Abbreviations: BSI, bloodstream infection; CrCl, creatinine clear‐
ance; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LT, liver 
transplant.
TA B L E  1   (Continued)TA B L E  1   Characteristics of liver transplant recipients included 
in the study (n = 27)
Characteristic N = 27
Age (y, IQR) 57 (52.0‐60.3)
Males (%) 20 (74)
Reason for liver transplantation (%)
HCV‐related cirrhosis 7 (26)
HCV + HCC 3 (11)
HIV/HCV + HCC 2 (7)
HBV‐related cirrhosis 2 (7)
HBV + HCC 3 (11)
Alcohol‐related 5 (19)
Alcohol + HCC 2 (7)
Primary biliary cirrhosis 2 (7)
Fulminant HBV 1 (4)
Charlson comorbidity score (IQR) 3.3 (2.0‐4.5)
Renal impairment (%)
Mild (CrCl 50‐80 mL/min) 13 (48)
Moderate (CrCl 31‐49 mL/min) 7 (26)
Severe (CrCl 10‐30 mL/min) 4 (15)
Albumin g/L (IQR) 25.7 (19.0‐30.3)
Creatinine mg/dL (IQR) 1.20 (0.98‐1.69)
BMI (kg/m2) 22.9 (20.6‐26.9)





Candida species (%) 19 (70)
C albicans 11/19 (58)
C glabrata 4/19 (21)
C parapsilosis 2/19 (11)
C tropicalis 1/19 (5)
Mixed (C albicans and glabrata) 1/19 (5)
Timing from LT (d, IQR) 42 (10‐406)
Median duration of hospitalization (d, 
IQR)
45 (29‐62)
MELD score 17.5 (14.0‐23.5)
Hospitalization in ICU (%) 8 (33)
Concomitant antimicrobial therapy (%) 18 (67)
Fever (%) 12 (44)







Enterococcus spp 6/12 (50)
(Continues)
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fluconazole doses had median Cmin of 8.83 mg/L (IQR 4.8‐10.5) at 
steady state and all reached Cmin >9 mg/L during treatment. No 
changes in CrCl or liver enzymes were detected during fluconazole 
treatment. In 12 (44%) patients with high fluconazole Cmin (more 
than twice the target level), dose reduction was performed and flu‐
conazole Cmin maintained >10 mg/L.
Fluconazole dose significantly correlated with Cmin (rs = 0.560, 
P = 0.002), while other parameters such as age, albuminemia, BMI, 
and CrCl did not appear significantly associated with fluconazole lev‐
els (Table S1).
Table 2 compares fluconazole Cmin in different patient groups. 
Although decreased levels of fluconazole were documented for pa‐
tients with low albuminemia (<20 g/L) and high BMI (>25), the uni‐
variate analysis did not show significant influence of demographic or 
laboratory parameters on fluconazole Cmin.
Dosing adaptation of concomitant immunosuppressive therapy 
was required in 17/27 (63%) patients: 11/17 (65%) receiving tacroli‐
mus (TAC), 5/8 (63%) receiving cyclosporine A (CsA), and 1/2 (50%) 
treated with everolimus (EVR). Mean percentage dose reduction was 
42% for TAC, 36% for CsA, and 13% for EVR.
In five cases (three BSI and two biliary infections), microbio‐
logical cultures were available at the end of antifungal treatment, 
and all documented Candida eradication. Median fluconazole 
Cmin among patients with microbiological eradication was 
10.7 mg/L (IQR 8.3‐15.5). Eight (30%) patients were admitted in 
the ICU and 3 (11%) patients presented with sepsis. None of the 
patients received renal replacement therapy or treatment with 
extracorporeal membrane oxygenation (ECMO) while receiving 
fluconazole.
Recurrent Candida biliary or abdominal infections within 
3 months from the previous episode were reported in 2 (7%) pa‐
tients. Switch of antifungal treatment from fluconazole to caspo‐
fungin or voriconazole was performed in 4/27 (15%) cases (three 
patients with C glabrata and one with C parapsilosis infection) due 
to worsening conditions. Overall all‐cause in‐hospital mortality was 
9/27 (33%). Median time from fluconazole therapy initiation and 
death was 44 days (IQR 32‐80). In 4/9 (44%) cases, mortality ap‐
peared related to the presence of candidiasis.
Mortality was significantly higher among patients with lower fluco‐
nazole Cmin either at first TDM (8.5 mg/L, IQR 5.7‐10.7 and 12.7 mg/L, 
IQR 8.9‐20.2, P = 0.02) or at subsequent occurrences (10.4 mg/L, IQR 
7.10‐11.1 and 15.1 mg/L, IQR 8.9‐21.1, P = 0.03; Figure S1). Univariate 
analysis showed that mortality was significantly higher among patients 
with decreased serum albumin levels (P = 0.04) and those hospital‐
ized in the ICU (P = 0.01) (Table 3). Although mortality was higher for 
fluconazole	MIC	>1	mg/L	vs	MIC	≤1	mg/L	(50%	vs	22%,	respectively,	
P = 0.52), the difference was not statistically significant.
Clinical success was documented in 15 (56%) patients. Univariate 
analysis identified serum albumin >20 g/L and fluconazole Cmin 
>11 mg/L as factors associated with clinical success (Table 4). 
Multivariate analysis showed that only Cmin >11 mg/L was an in‐
dependent factor significantly associated with clinical success (OR 
8.78, 95% CI 1.13‐67.8, P = 0.04).
Areas under the receiver‐operating characteristic (ROC) curve 
showed that fluconazole Cmin >11 mg/L had highest sensitivity, spec‐
ificity, and Youden's Index in predicting clinical success (Table S2 and 
Figure S2).
4  | DISCUSSION
As previously reported, we observed high (>30%) in hospital mortal‐
ity in LTR with Candida infections.1,19 The intrabdominal site was 
also confirmed to be a common site for candidiasis among LTR.14 
Fluconazole still represents the drug of choice in the treatment of 
candidiasis for patients who are clinically stable and did not report 
recent exposure to azoles.6,7,20 Furthermore, the role of fluconazole 
in deep‐seated infections is supported by its excellent tissue pen‐
etration.21 We previously showed that intra‐abdominal penetration 
of fluconazole was very high in three LTR with intra‐abdominal can‐
didiasis (eg, two cases of cholangitis and one of peritonitis), rang‐
ing from 50% to 85%.16 In the same study, TDM‐guided fluconazole 
therapy was performed with maintenance of plasma Cmin at around 
15 mg/L for 14 days, resulting in clinical resolution of the infection.16
TDM of fluconazole is generally not recommended due to its 
approximately linear and predictable PK behavior, so that dosing 
adaptations based on CrCl estimates are considered appropriate in 
clinical practice.10 However, it should not be overlooked that in LTR 
the reliability of CrCl in predicting renal function was shown to be 
poor.11 Fluconazole TDM‐guided dosing adjustments may be advis‐
able in this population since adaptation based only on CrCl estimates 
could result in inaccurate fluconazole exposure. We also confirmed 
that in LTR low fluconazole maintenance dosages (100‐200 mg daily) 
appeared sufficient to achieve optimal probability of target attain‐
ment against C albicans.12,16
Liver toxicity associated with fluconazole use has been re ‐
ported.15,22 No clear association between fluconazole concentrations 
and liver function, however, has been documented to justify fluco‐
nazole TDM for toxicity purposes.10 In our study, drug reduction was 
TA B L E  2   Fluconazole median Cmin (mg/L) in different patient 
groups
Characteristic Yes No P value
Male sex 10.7 (7.9; 13.4) 12.8 (6.3; 17.1) 0.66
ICU admission 11.0 (6.3; 16.0) 10.9 (8.6; 19.2) 0.83
Serum albumin 
<20 g/L
7.9 (6.2; 10.5) 12.4 (8.9; 19.3) 0.07
CrCl <50 mL/min 13.8 (7.5; 22.4) 11.0 (7.4; 12.7) 0.32
BMI >25 7.9 (6.2; 11.0) 12.4 (8.6; 19.3) 0.60
MELD >15 12.6 (9.1; 17.6) 9.6 (6.2; 13.2) 0.24
Note: Median fluconazole Cmin reported in the table were measured 
at first therapeutic drug monitoring; target of Cmin was 10 mg/L, with 
dose increase recommended for Cmin <8 mg/L. Results are expressed as 
median and interquartile range (IQR) of fluconazole median Cmin (mg/L).
Abbreviations: BMI, body mass index; ICU, intensive care unit; MELD, 
model for end stage liver disease.
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suggested for high fluconazole Cmin (eg, more than twice the target 
level) in order to maintain a concentration target around 10 mg/L. In 
our study, fluconazole Cmin up to 31 mg/L were not associated with 
changes in liver or renal function during treatment.
The PK/PD parameter that best predicts the outcome for flu‐
conazole is the AUC/MIC ratio.23,24	 AUC/MIC	 ratios	 ≥55.2	 were	
generally associated with favorable clinical outcomes,16 but higher 
target values (>100) have been advocated for certain categories of 
patients, such as pediatric and critically ill patients, especially those 
receiving hemofiltration.10,25,26 Our fluconazole Cmin target was set 
at around 10 mg/L. Although rough, the approach of targeting Cmin 
at this value is in line with the intent of achieving AUC/MIC ratio 
of at least 100 against all of the fluconazole‐susceptible (EUCAST 
clinical breakpoint 2 mg/L) strains of Candida spp [10 mg/L × 24 h
ours)/2 mg/L = 120]. A previous study including pediatric patients 
receiving fluconazole showed increased microbiological eradica‐
tion rates for fluconazole Cmin >11 mg/L.
9 Although we could not 
confirm a positive impact of Cmin on Candida eradication due to the 
limited number of patients with repeated microbiological cultures, 
we observed that comparable cut‐off value (Cmin >11 mg/L) were 
associated with clinical success in our study. Although decreased 
Cmin were more common among patients with Candida infection 
who died during hospitalization compared to survivors, the small 
sample size and potential confounding factors prevented us from 
drawing conclusions about the impact of fluconazole concentrations 
on mortality. Finally, although increased fluconazole MICs appeared 
correlated with higher mortality rates, this result was not statisti‐
cally significant, probably because of the limited number of patients 
enrolled in the study.
Univariate analysis showed that hypoalbuminemia appeared asso‐
ciated with poor outcomes. No significant correlations, however, were 
shown between fluconazole Cmin and albumin serum levels in our cohort. 
As previously reported, the unbound fraction of fluconazole should not 
be affected by hypoalbuminemia since only a small moiety (12%) of flu‐
conazole molecules is bound to plasma protein.27 Hypoalbuminemia, 
however, has been linked with increased mortality among patients on 
liver transplant waiting list.28,29 There is currently no consensus to sup‐
port albumin supplementation in this patient population.30,31
In conclusion, the findings of a statistically significant associa‐
tion between fluconazole Cmin >11 mg/L and clinical success appear 
TA B L E  3   Univariate analysis of factors associated with in‐
hospital mortality
Factor Lived (18) Died (9)
P 
value
Male sex (%) 13 (87) 7 (78) 1.00
Age (y, IQR) 54.0 (51.8‐59.0) 60.0 (54.0‐62.5) 0.32
Charlson score (IQR) 4.0 (2.8‐5.0) 3.0 (2.0‐3.8) 0.08
BMI, kg/m2 (IQR) 22.3 (20.6‐23.9) 26.8 (22.0‐28.0) 0.08
Time from LT(d, IQR) 160 (14.0‐432.0) 40 (3.0‐137.5) 0.11
Serum albumin, g/L 
(IQR)
26.3 (23.8‐31.2) 19.0 (16.0‐25.3) 0.04
CrCl, ml/min (IQR) 57.9 (39.3‐68.3) 73.6 (49.7‐88.2) 0.20
Concomitant bacte‐
rial infection (%)
7 (47) 5 (56) 0.68
Concomitant bacte‐
rial BSI (%)
4 (27) 3 (33) 0.65
Non albicans Candida 
(%)
4/12 (33) 4/6 (67) 0.31
Median MELD score 
(IQR)
14.5 (10.0‐18.0) 17.0 (15.0‐20.0) 0.10
aMean fluconazole 
Cmin, mg/L (IQR)
12.7 (8.9‐20.2) 8.5 (5.7‐10.7) 0.02
ICU stay (%) 2 (13) 6 (67) 0.01
Median hospital stay 
(d, IQR)
33.0 (21.8‐55.5) 62.0 (47.0‐134.5) 0.07
Note: Results are expressed as percentage (%) or median and interquar‐
tile range (IQR).
Abbreviations: BMI, body mass index; BSI, bloodstream infections; CrCl, 
creatinine clearance; ICU, intensive care unit; LT, liver transplant; MELD, 
model for end stage liver disease.
aMeasured at first therapeutic drug monitoring. Statistically significant 
values are shown in bold. 
Characteristic
Univariate analysis Multivariate analysis
OR (95% IC) P value OR (95% IC) P value
Age <60 y 0.80 (0.16‐4.02) 0.78   
Charlson score <4 1.36 (0.28‐6.58) 0.70   
Mean CrCl >50 mL/
min
0.63 (0.12‐3.32) 0.58   
aFluconazole Cmin 
>11 mg/L
13.0 (1.92‐87.99) 0.01 8.76 (1.13‐67.77) 0.04
No ICU stay 0.35 (0.06‐1.93) 0.23   
Albuminemia 
>20 g/L
14.0 (1.37‐142.89) 0.03 8.31 (0.66‐104.26) 0.10
Note: Variables with statistically significant association on univariate analysis (fluconazole Cmin, 
albuminemia) were included in a multivariable binary logistic regression model.
Abbreviations: CrCl, creatinine clearance; ICU, intensive care unit.
aMeasured at first therapeutic drug monitoring. Statistically significant values are shown in bold. 
TA B L E  4   Univariate and multivariate 
analysis of factors associated with clinical 
success
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to support our choice of performing TDM in LTR with candidiasis, 
although the results should be interpreted with caution due to the 
limited number of patients enrolled in the study. To the best of our 
knowledge, however, this is the first study analyzing the potential 
role of fluconazole TDM in improving clinical outcomes of liver 
transplant recipients with candidiasis.
Our study has several limitations. Firstly, due to the retrospec‐
tive nature of the study and the site of Candida infections, that 
was abdominal in the majority of cases, a systematic assessment 
of the microbiological resolution of the infection was unfeasible. 
Secondly, the analysis of the association between fluconazole lev‐
els and outcome among severely ill (eg, ICU admitted) patients or 
patients with non albicans candidiasis was unfeasible due to the 
limited sample size. Thirdly, the retrospective nature of the study 
limits the generalizability of the findings, considering that other 
factors other than Candida infection could have been implicated 
in patients’ outcome. This, however, represents a common lim‐
itation in studies assessing the outcome of patients with invasive 
candidiasis that is often affected by multiple confounders such 
as patients’ complexity and multiple comorbidities. Finally, we 
recognize that TDM based only on Cmin determination is a rough 
measurement and did not allow an appropriate estimation of AUC, 
potentially causing underestimation of drug exposure.
In conclusion, our study suggests that TDM of fluconazole Cmin 
may be advisable in LT recipients with suspected or documented 
candidiasis. Prospective studies in larger cohorts are warranted to 
confirm the utility of TDM in LTR and to further analyze the correla‐
tion between fluconazole exposure and clinical outcome.
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